Tablets

Available at NUH only:

• Approved in accordance with compassionate use scheme for treating Hormone Receptor (HR) positive, HER2 negative metastatic breast cancer in combination with fulvestrant, pre-treated with aromatase inhibitors. (Existing patients only.
• Approved in accordance with NICE TA579 with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
• Approved in accordance with NICE TA563, with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

Tablets

Available at NUH only:

• Approved as per NICE TA571 for treating ALK-positive advanced non-small cell lung cancer after crizotinib.
• Approved in accordance with the National Cancer Drugs Fund for treating ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor

Capsule

NUH: Approved in accordance with NICE TA516 for treating medullary thyroid cancer.

Capsule

Approved in accordance with NICE:

• TA406 for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.
• TA422 for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.
• TA529 for treating ROS1-positive advanced non-small-cell lung cancer.

Tablets 2.5mg, 5mg, 10mg

• Approved in accordance with NICE TA421; Everolimus with exemestane for treating advanced breast cancer after endocrine therapy.
• NUH approved in accordance with NICE TA432; Everolimus for advanced renal cell carcinoma after previous treatment.
• NUH approved in accordance with NICE TA449 for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
• NUH approved in accordance with NICE TA498; Everolimus with lenvatinib (Kisplyx®) for previously treated advanced renal cell carcinoma

Tablets 2.5mg, 5mg, 10mg

Available at NUH only:

• Approved for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) in line with NHS England commissioning policy.
• Blueteq submission required
• Approved in line with NHSE Commissioning Policy for refactory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above)

Available through Homecare for NUH patients. Please contact pharmacy medicines homecare team for further information.

Tablets

• Approved in accordance with NICE TA192 for NSCLC
• Patient access scheme exists. Further information can be found here
• Gefitinib (Iressa^®) is not recommended for treating non small cell lung cancer that has progressed after chemotherapy as per NICE TAG 374
  
  At SFH:
• CANNOT be kept as stock in pharmacy. For first cycle, orders can only be processed after purchasing has received a Patient Registration Form (1) signed by the Oncologist.
• Read Instructions for Dispensary for more detailed information.

Tablets

Available at NUH only:

• Approved in accordance with NICE TA642, for treating relapsed or refractory acute myeloid leukaemia
• Approved at NUH in accordance with NHS England’s interim treatment options available during the COVID-19 pandemic only. For review post March 2021: For use, instead of chemotherapy, in relapsed or refractory FLT3-mutation-positive Acute Myeloid Leukaemia in adults.

Tablets
NUH only:

• Approved in accordance with NICE TA326 & TA209: for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours and the adjuvant treatment.
• Approved in accordance with NICE TA70 & TA251: for chronic myeloid leukaemia.
• Approved in accordance with NICE TA425: for high dose therapy for CML - not recommended.
• Approved in accordance with NICE TA426: for untreated, chronic-phase Philadelphia-chromosome-positive CML in adults
• Approved for adults and children with newly diagnosed Ph+ acute lymphoblastic leukaemia
  
  
• Glivec^® brand must be used for Gastrointestinal Stromal Tumours (GIST)

 SFH

• Existing patients to remain on homecare and no new patients to be on homecare

Oral solution

Available at NUH only:

• Approved in accordance with the National Cancer Drugs Fund and NICE TA630 for treating NTRK fusion-positive solid tumours in adults and children.

Tablet

• Approved in accordance with NICE TA653 for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
• Approved in accordance with NICE TA654 for untreated EGFR mutation-positive non-small-cell lung cancer

Tablets

• Approved in accordance with NICE TA488 for previously treated unresectable or metastatic gastrointesrinal stromal tumors
• Approved in accordance with NICE TA555 for previously treated advanced hepatocellular carcinoma
• SFH: Confirm funding by contacting the HCD Team on 4660

Tablets

NUH approved in accordance with:

• NICE TA474 for treating advanced hepatocellular carcinoma - only for people with Child-Pugh grade A liver impairment
• NICE TA535 for treating differentiated thyroid cancer after radioactive iodine

At SFH: Do not authorise before contacting High Cost Drugs team (4657) or Cancer services pharmacist (3156).

Capsule

Available at NUH only:

• Approved in accordance with NICE TA643, for the treatment of ROS1-positive advanced non-small-cell lung cancer. Funding available from the Cancer Drugs fund until routine commisioning.
• Approved in adults and children over 12 years old in accordance with NICE TA644 for treating NTRK fusion-positive solid tumours